NCT01232075

Brief Summary

The aim of this randomized controlled trial is to compare the efficacy of extended letrozole regimen (2.5mg/day from cycle day 1 to 9) with clomiphene citrate (100 mg/day from cycle day 3 to 7) in women with unexplained infertility undergoing superovulation and intrauterine insemination .

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
214

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Sep 2008

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

November 1, 2010

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 2, 2010

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
Last Updated

July 12, 2011

Status Verified

July 1, 2011

Enrollment Period

2.2 years

First QC Date

November 1, 2010

Last Update Submit

July 11, 2011

Conditions

Keywords

Letrozole ,Clomiphene citrate , IUI,unexplained infertility

Outcome Measures

Primary Outcomes (1)

  • Clinical pregnancy rate

    Presence of intrauterine gestational sac detected by transvaginal ultrasound

    5 weeks after intrauterine insemination

Secondary Outcomes (1)

  • Ongoing Pregnancy Rate

    18 weeks after intrauterine insemination

Study Arms (2)

Extended letrozole regimen

EXPERIMENTAL
Drug: Extended letrozole regimen

Clomiphene citrate regimen

ACTIVE COMPARATOR
Drug: Clomiphene citrate regimen

Interventions

Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 . Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection . Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration. Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .

Also known as: letrozole 2.5mg/day from cycle day 1 to 9
Extended letrozole regimen

Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7. Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection . Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration. Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy .

Also known as: Clomiphene citrate 100mg/day from cycle day 3 to 7
Clomiphene citrate regimen

Eligibility Criteria

Age18 Years - 37 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients with unexplained infertility
  • Age between 18 - 37 years
  • Period of infertility \> 1 year
  • Patent Fallopian tubes detected by hysterosalpingography and/or laparoscopy
  • Normal basal luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin concentrations
  • Normal recent semen analysis (according to World Health Organization criteria)

You may not qualify if:

  • FSH\> 10 IU/L
  • Irregular menstrual cycles
  • Polycystic ovary syndrome
  • Endometriosis
  • Endocrinologic disorders
  • Systemic disease contraindicating pregnancy
  • Previous IUI cycles
  • liver or kidney diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ahmed Elgazzar hospital

Cairo, Egypt

Location

Cairo university hospital

Cairo, Egypt

Location

Related Publications (3)

  • Badawy A, Mosbah A, Tharwat A, Eid M. Extended letrozole therapy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a novel protocol. Fertil Steril. 2009 Jul;92(1):236-9. doi: 10.1016/j.fertnstert.2008.04.065. Epub 2008 Aug 15.

    PMID: 18706549BACKGROUND
  • Badawy A, Elnashar A, Totongy M. RETRACTED: Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial. Fertil Steril. 2009 Oct;92(4):1355-1359. doi: 10.1016/j.fertnstert.2008.06.013. Epub 2008 Aug 9.

    PMID: 18692823BACKGROUND
  • Fouda UM, Sayed AM. Extended letrozole regimen versus clomiphene citrate for superovulation in patients with unexplained infertility undergoing intrauterine insemination: a randomized controlled trial. Reprod Biol Endocrinol. 2011 Jun 21;9:84. doi: 10.1186/1477-7827-9-84.

MeSH Terms

Conditions

Infertility

Interventions

LetrozoleClomiphene

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

NitrilesOrganic ChemicalsTriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsStilbenesBenzylidene CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Usama M Fouda, M.D, PhD

    Cairo University

    STUDY CHAIR
  • Ahmed M Sayed, M.D, PhD

    Cairo University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 1, 2010

First Posted

November 2, 2010

Study Start

September 1, 2008

Primary Completion

November 1, 2010

Study Completion

December 1, 2010

Last Updated

July 12, 2011

Record last verified: 2011-07

Locations